WASHINGTON, DC, October 30, 2026 (EZ Newswire) -- The American Kratom Association is calling on The New York Times to publish a substantial correction or fully retract its Oct. 28, 2026, article, “Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying,” charging that the newspaper presented a materially misleading account of the Drug Enforcement Administration's revised federal scheduling proposal for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI).

In a letter addressed to The New York Times publisher A.G. Sulzberger, the AKA challenges the article's central portrayal of the Trump administration's action as a retreat from efforts to control dangerous opioid products. The AKA argues that the report failed to adequately explain two critical provisions of the revised DEA proposal that materially affect which products would be subject to Schedule I controls.

First, the revised DEA rule establishes a single combined concentration threshold for both 7-OH and MGPI. Second, it adds an independent 100-to-1 alkaloid-ratio requirement that can trigger Schedule I controls even when the combined concentration falls below the numerical limit. The revised proposal therefore includes an additional way to identify products containing disproportionately elevated concentrations of potent opioid-active compounds.

"The New York Times owes its readers a correction that explains what the DEA actually proposed, rather than presenting a misleading political narrative that leaves out critical regulatory requirements," said Mac Haddow, Senior Fellow on Public Policy for the American Kratom Association. "The revised DEA proposal does not give manufacturers separate allowances for 7-OH and mitragynine pseudoindoxyl. It combines those two potent opioid compounds under a single concentration threshold and adds a second, independent 100-to-1 ratio test. Ignoring those provisions fundamentally distorts the scope and intent of the federal action."

AKA Demands Prominent Correction, Revised Headline, or Full Retraction

The AKA’s letter calls for The New York Times to correct the article's treatment of the combined 7-OH/MGPI concentration threshold, explain the independent 100-to-1 ratio test, clarify that the October action remains a Notice of Intent rather than an effective final order, and distinguish scheduling thresholds from findings of product safety or market authorization.

The Association also requests reconsideration of the headline and correction of the information disseminated through republication and syndication.

If the newspaper cannot adequately correct its central characterization without fundamentally rewriting the article, the AKA requests a complete retraction.

"This is not a disagreement about whether journalists should scrutinize government decisions, lobbying, or political contributions. Of course they should," Haddow said. "But legitimate scrutiny does not excuse leaving out material provisions of the actual federal rule. The New York Times has a responsibility to accurately explain what the government proposed, including the single combined threshold for 7-OH and MGPI and the independent 100-to-1 ratio requirement."

“When an article misleads readers about a federal drug-control action with serious public health consequences, the appropriate response is a prominent correction — not silence, and not a minor clarification buried where readers will never see it. If the fundamental narrative cannot be corrected, the article should be retracted," Haddow concluded.

About American Kratom Association (AKA)

The American Kratom Association is a consumer advocacy organization dedicated to protecting access to safely manufactured, properly labeled natural kratom products. The AKA advocates for science-based regulation, enforceable manufacturing standards, independent product testing, accurate labeling, and decisive action against adulterated, chemically manipulated, and dangerously formulated opioid products.

Disclaimer

The American Kratom Association (AKA) is a 501(c)(4) nonprofit advocacy organization. This press release is issued for informational and public policy purposes only. The information contained herein reflects policy analysis regarding federal administrative actions and does not constitute legal, regulatory, or medical advice. Statements regarding natural kratom leaf products have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat, cure, or prevent any disease. Readers should consult qualified healthcare professionals regarding personal medical decisions.

Media Contact

Mac Haddow
Senior Fellow on Public Policy
press@americankratom.org
+1 571-294-5978

###

SOURCE: American Kratom Association (AKA)

For questions regarding this release or its content, contact hello@eznewswire.com for immediate assistance.